B8F Stock Chart & Stats
Currently, no data available
Please return soon. This page is being updated.
Bulls Say, Bears Say
Bulls Say
Strong Gross MarginAn approximately 83% gross margin shows that Biofrontera’s products retain substantial value after direct costs. If maintained, this provides economic room to support research, commercialization, and operating improvements as revenue scales, even though overall profitability remains negative.
Conservative LeverageVery low leverage limits interest burdens and reduces dependence on creditors compared with a highly indebted business. This gives Biofrontera greater flexibility to manage volatility and pursue its dermatology strategy, although continued losses still require careful capital management.
Recurring PDT Product ModelThe model combines a prescription dermatology product with related treatment equipment, while gel consumption can recur with each in-office PDT procedure. This creates a potentially repeatable clinical revenue base tied to practitioner adoption and ongoing treatment activity.
Bears Say
Revenue VolatilityThe sharp post-2023 revenue decline and limited 2025 recovery indicate an unstable top line rather than dependable growth. Such volatility makes operating leverage harder to achieve, complicates planning, and weakens the company’s ability to absorb ongoing commercial and development costs.
Persistent Cash BurnRepeated negative operating and free cash flow show that the core business has not yet funded its own activities consistently. Continued cash consumption can increase reliance on external funding and constrain investment capacity unless revenue growth or cost reductions materially improve.
Ongoing Losses And Shrinking EquityPersistent net losses are eroding the equity base, with book equity falling substantially over recent years and 2025 return on equity remaining negative. This weakens financial resilience over time and can reduce the resources available to support commercialization or absorb further setbacks.
Biofrontera News
B8F FAQ
What was Biofrontera AG’s price range in the past 12 months?
Currently, no data Available
What is Biofrontera AG’s market cap?
Biofrontera AG’s market cap is CHF17.55M.
When is Biofrontera AG’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Biofrontera AG’s earnings last quarter?
Currently, no data Available
Is Biofrontera AG overvalued?
According to Wall Street analysts Biofrontera AG’s price is currently Undervalued.
Does Biofrontera AG pay dividends?
Biofrontera AG does not currently pay dividends.
What is Biofrontera AG’s EPS estimate?
Biofrontera AG’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Biofrontera AG have?
Currently, no data Available
What happened to Biofrontera AG’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Biofrontera AG?
Currently, no hedge funds are holding shares in CH:B8F
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Biofrontera Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Fundamentals
Return on Equity
-127.78%
Trailing 12-Months
Asset Growth
―
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Biofrontera AG
Biofrontera AG operates as a biopharmaceutical company specializing in dermatology. It conducts research, development, and commercialization of skin-related products across Germany, Spain, the United Kingdom, the broader European continent, the United States, and other global markets. Its primary products include Ameluz and the BF-RhodoLED lamp, which are utilized for treating mild to moderate actinic keratoses on the face and scalp, addressing field cancerization, and managing fatal squamous cell carcinoma. The company also supplies the RhodoLED XL lamp, engineered for treating multiple interspersed lesions, alongside Belixos, a cosmetic range developed for irritated and sensitive skin. Biofrontera AG maintains a licensing and supply agreement with Maruho Co., Ltd. Founded in 1997, the company's corporate headquarters are situated in Leverkusen, Germany.
Eckert & Ziegler Strahlen und Medizintechnik
―
Evotec
―
Merck KGaA
―
Heidelberg Pharma AG
―
Dermapharm Holding SE
―